about
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseT-cell exhaustion in allograft rejection and toleranceInflammatory responses in hypoxic ischemic encephalopathyNo quiet surrender: molecular guardians in multiple sclerosis brainEpitopes in α8β1 and other RGD-binding integrins delineate classes of integrin-blocking antibodies and major binding loops in α subunitsMRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.Use of natalizumab in multiple sclerosis: current perspectives.Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.Role reversal: infiltrating T cells protect the brain.Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination.Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up studyProfile of Lawrence Steinman.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.Concomitant granule cell neuronopathy in patients with natalizumab-associated PMLEthical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.A Journey in Science: The Privilege of Exploring the Brain and the Immune System.Cytotoxic-T-lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.Fibronectin in tissue regeneration: timely disassembly of the scaffold is necessary to complete the build.The role of innate and adaptive immunity in Parkinson's disease.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.Perception of risk and shared decision making process in multiple sclerosis.Anti-JC virus seroprevalence in a Finnish MS cohort.MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions.Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia.The discovery of natalizumab, a potent therapeutic for multiple sclerosis.MRI pattern in asymptomatic natalizumab-associated PML.
P2860
Q26770664-5FE39C0D-54AC-4B40-90D0-8ABAD085D629Q26822941-787D32F7-8FB7-4D14-B6CD-8BD77D458B0DQ26865338-E4BF456C-D04D-4331-9FE7-1C94CDA607D7Q27001711-85D9BACA-B903-4117-8CDE-514CEAECEF79Q28084633-1C5E0C68-1E8B-4B79-81D9-09544AF51687Q28607846-C859ADFA-4321-4F5F-BA70-AC4779214558Q30981999-01FE2174-5E31-42D7-B65B-DD338CB8370AQ31114633-94A3232B-DF68-4821-A6F4-C7AFDEEFF212Q33605681-139C7E60-19C7-4ABC-A58B-404D6B74CCECQ33965415-B44D977D-1D83-4AF3-8BEF-94C481A5CC69Q34562841-FAED821A-FB2F-4395-82CB-CEC851A2CDCBQ35056732-22FAAD92-EAEE-4C57-854A-382F97397828Q35154391-2B29B925-7A86-4401-BC85-B77B6776122AQ36110582-46CA4EDA-9780-459B-A301-3AAD85DB7173Q36598882-0B3DD55A-2183-4AD6-A49F-0A58CCD67592Q36767522-0273D501-1050-44FF-A263-0D2135F465C3Q36783871-7DE6F4A1-E282-4CD9-971C-89049F35C8A5Q36885357-19C12AC9-2583-4AAF-90FB-CC61754BFC49Q36975701-0090B594-7587-4D7E-AC18-57028F8E3C6AQ37217037-8E0DB5E2-EE6F-496A-B421-895963459540Q37643927-68108B29-E839-4E00-A1D3-218E43BF4706Q37702072-6B30DC7D-0E88-413C-8A55-BA9EFB419F04Q38113681-769600A0-9AE1-4FC2-AC68-BF581EFF2ABEQ38166155-C6D41322-B09F-4AC3-8029-7F66C25EBEBEQ38167347-215B8657-751E-4B87-8F4B-28B43F2270F5Q38184645-14800D71-BC48-4BA4-84EB-1844E5A414FEQ38207555-7E0D734E-D0B3-455A-99CB-8CE50B7EEBCCQ38207560-83413B20-EA5C-4EC1-93FC-E721D4A2DE4FQ38248635-94B115FF-1F3F-45CD-A681-0C2A4F900F58Q38837567-9DEB90C1-22A5-4439-BCA6-9387488DC844Q38911148-AE0C8B96-2E67-4AB0-ACBF-DD8634B7943EQ40565210-EC511398-8B19-450D-91A4-2CE8101E0897Q40619670-234C1675-8C54-4EF2-BFD2-56D34A02ECF5Q41126166-2209016E-4EE6-4F39-A02D-8E6DDF6A68E1Q41361912-18673443-E741-4506-998B-D4E2F860403FQ41381386-855479EA-ED05-4C9A-B24A-17D104782816Q41455235-DD47937C-466A-4065-9CBF-5A8D83E2AB6EQ41511386-64F5456D-891F-4A64-BAF0-85724D764B51Q41666154-6B0CF897-DE12-4C1A-B5EA-6996DF1C065CQ41745436-CD00740A-A6DD-432A-9D9C-8495C3DA8F4F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Natalizumab: bench to bedside and beyond.
@en
type
label
Natalizumab: bench to bedside and beyond.
@en
prefLabel
Natalizumab: bench to bedside and beyond.
@en
P2093
P1433
P1476
Natalizumab: bench to bedside and beyond.
@en
P2093
Chris Polman
David Clifford
David Miller
Lawrence Steinman
Richard Rudick
P304
P356
10.1001/JAMANEUROL.2013.598
P407
P577
2013-02-01T00:00:00Z